Janux Therapeutics Inc (NASDAQ: JANX) kicked off on Friday, up 5.30% from the previous trading day, before settling in for the closing price of $50.00. Over the past 52 weeks, JANX has traded in a range of $5.65-$58.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 32.66% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -16.00%. With a float of $34.43 million, this company’s outstanding shares have now reached $46.25 million.
In an organization with 64 employees, it is important to assess its efficiency.
Janux Therapeutics Inc (JANX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 33.35%, while institutional ownership is 57.78%. The most recent insider transaction that took place on Nov 13 ’23, was worth 4,988,643. In this transaction 10% Owner of this company bought 849,854 shares at a rate of $5.87, taking the stock ownership to the 849,854 shares. Before that another transaction happened on Nov 13 ’23, when Company’s Acting Chief Financial Officer bought 849,854 for $5.87, making the entire transaction worth $4,988,643. This insider now owns 849,854 shares in total.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 52.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.00% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Take a look at Janux Therapeutics Inc’s (JANX) current performance indicators. Last quarter, stock had a quick ratio of 26.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 336.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.70 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.71 million. That was better than the volume of 0.76 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 74.61%. Additionally, its Average True Range was 4.28.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 88.13%, which indicates a significant increase from 83.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.12% in the past 14 days, which was lower than the 206.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.53, while its 200-day Moving Average is $15.21. However, in the short run, Janux Therapeutics Inc’s stock first resistance to watch stands at $55.10. Second resistance stands at $57.54. The third major resistance level sits at $60.33. If the price goes on to break the first support level at $49.87, it is likely to go to the next support level at $47.08. Assuming the price breaks the second support level, the third support level stands at $44.64.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
The company with the Market Capitalisation of 2.72 billion has total of 51,660K Shares Outstanding. Its annual sales at the moment are 8,080 K in contrast with the sum of -58,290 K annual income. Company’s last quarter sales were recorded 2,460 K and last quarter income was -11,760 K.
